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Abstract  Article Info 
Introduction: Nasopharyngeal carcinoma (NPC) is in the fourth place according to the most most common 
malignancies in Indonesians. Three types of nasopharyngeal carcinoma are squamous cell, non-keratinizing, 
and undifferentiated carcinoma. 
Case report: A 51-year-old man came to the ENT-Head and Neck Surgery Outpatient clinic of General Hospital 
Haji Adam Malik Medan on November 2, 2020 with main complaint of lump on the neck and nasal congestion. 
The patient underwent a contrast-enhanced nasopharyngeal MSCT scan with the result: T2N0M0. The 
histopathology results: Non-Keratinizing Squamous Cell Carcinoma. The patient was given 70 gy of 
Chemoradiation (CRT) followed by adjuvant chemotherapy with Cisplatin + 5 Fu.   
Conclusion: There was no visible mass on the nasopharynx after using this combination therapy.  
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1. CASE REPORT 
A 51-year-old man came to the ENT-Head and Neck Surgery Outpatient 
clinic of General Hospital Haji Adam Malik Medan on November 2, 2020 with 
main complaint of lump on the neck and nasal congestion. This complaint felt by 
the patient since the previous 7 months. Previous history of tinnitus in the ears 
denied. History of habitual smoking was found in the last 30 years ago. History 
of consuming salted fish was found. There was no history of epistaxis. The 
patient underwent a contrast-enhanced nasopharyngeal MSCT scan on 
November 9, 2020 with the result: T2N0M0. The histopathology result on 
November 23, 2020: Non-Keratinizing Squamous Cell Carcinoma. The patient 
was given 70 gy of Chemoradiation (CRT) then adjuvant chemotherapy with 
Cisplatin + 5Fu during 3 cycles. The patient was evaluated on April 2021 and 
from the contrast enhanced nasopharyngeal MSCT Scan, the results was: there 
was no visible mass on the nasopharynx. 
2. DISCUSSION 
Nasopharyngeal carcinoma (NPC) is a tumor that comes from the 
epithelial cells that impound the surface and line the nasopharynx. Several 
case of this disease diagnosed in adol or adults in young age with 
undifferentiated type [1]. 
The risk factors that associated with nasopharyngeal carcinoma, such 
as genetic, environmental, smoking, salted fish consumption, especially 
EBV and oncogenesis [2]. Genetic is including p53 mutations and 
polymorphism. Nasopharyngeal carcinoma is in the fourth place of 
malignancy in head and neck in Indonesians. Most of the cases are 
associated with epstein barr virus (EBV) [3]. 
According to this case, this patient had history of salted fish 
consumption that might be contained of nitrosamine. Nitrosamine had 
association with EBV and nasopharyngeal carcinoma [4]. 
The incidence rate of nasopharyngeal carcinoma in Europe is 1.1 per 
100.000 and accounts for 4760 new cases per year [5], meanwhile 
nasopharyngeal carcinoma cases are often found in southern China and 
southeast Asia, and smaller numbers of cases are found in North Africa and 
the Arctic [6], most of them are men [7]. It means that nasopharyngeal 
carcinoma incidence is rely on race and geographical [8]. According to this 
case, males are three times affected by nasopharyngeal carcinoma [9]. 
The common sign  of nasopharyngeal carcinoma is unilateral hearing 
loss. The other symptoms like tinnitus, neck lump, nasal congestion, 
unilateral headache, nasal discharge with blood, and nasal bleeding. The 
growth of tumor can cause cranial nerves paralysis and manifests into 
diplopia, facial pain, ophtalmoplegia, and xeropthalmia [2]. The expansion 
of nasopharyngeal carcinoma into paranasopharyngeal space is marked by 
neck masses, cranial nerve palsy, nasal discharge with blood, and unilateral 
or bilateral auditory symptoms.  These symptoms are still detained for the 
patients in early stage of the disease. [10]. According to this case, this patient 
seeks a medical advisor 7 months after the sign’s occurrence, such as of neck 
lump and nasal congestion. There were still many of patients who comes to 
the health services after more than 6 months, even years [11].  
As the result of histological examination, the classification of 
nasopharyngeal carcinoma are : squamous cell, non-keratinizing, and 
undifferentiated [11]. The staging based on 3 informations, such as: the 
extent of the main tumor (T), the spread to nearby lymph nodes (N), and the 
spread (metastasis) to distant sites (M). All the categories are diagnosed by 
the result of history, biopsies and imaging test [12] and all these exams are 
provide in our centre. 
The staging procedures start from history taking, ENT physical 
examination, laboratory test, chest X-ray, nasopharyngoscopy, computed 
tomography (CT) scan or magnetic resonance imaging (MRI) of 
nasopharynx and base of skull and neck [13]. In this case, the diagnosis 
made by endoscopic-guided biopsy, histological examination, and 
performed the computed tomography (CT) scan [13].. As the result, the 
histological examination is non-keratinizing carcinoma and the staging is 
T2N0M0. 
The treatment strategy of nasopharyngeal carcinoma patients should be 
discussed in a multidisciplinary team. Patient with stage I treated by 
radiotherapy and for stage III, IVA, IVB are treated by radiotherapy and 
concurrent chemotherapy. According to this case, this patient did the 
concurrent chemotherapy that is recommended for stage II disease [14]. 







Then the induction cisplatin continue with radiotherapy with three cycles of 
concurrent cisplatin [15].  
Three cycles of adjuvant cisplatin-5FU has been a standard part of 
many concurrent chemoradiotherapy regimens. The standard agent used in 
concurrent chemotherapy–RT is cisplatin [16]. Concurrent chemotherapy 
that perform on Day 1, 22, and 43 every three weeks. With 100 mg/m2 
infusion. To lower the toxicity, the chemotherapy can be improve during 
concurrent chemotherapy [16].  
A total dose of 70 Gy is needed for tumor and fractional dose >2 Gy per 
daily fraction. Excessive acceleration with multiple fractions >1.9 
Gy/fraction should be avoided [17].  
Combination the lack of awakening, science about nasopharyngeal 
carcinoma and not aware to early signs lead to bad outcome and prognosis. 
Factors that related with a not good prognosis are connection to the cranial 
nerve, the stage of primary tumor, and refinement of skull base [11]. 
Metastasis is the common cause the breakdown of treatment [18]. Tumor 
volume is reflect to one of predictive factor. The primary tumor volume was 
one of prognostic factor of the local control rate and more predictive 
significance [19].  
3. CONCLUSION 
There was no visible mass on the nasopharynx after using this 
combination therapy. It can be shown that the staging tumor was reduce in 
CT-Scan evaluation after using that combination therapy. At the most 
important, early diagnosis in NPC was giving better result of this 
management. 
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